News & Events
“We are proud of our achievements and want to share our successes. You can find the latest information on our projects, publications and events here.”
TIKOMED’S ILB® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine
26 januari 2021
Viken – 7 January 2021 – A new study on TIKOMED’s lead drug candidate, ILB®, was published in npj Regenerative Medicine today….
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
14 september 2020
Viken – 14th September 2020 – A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying…
TIKOMED granted Orphan Medicinal Drug Designation for ILB® for the treatment of amyotrophic lateral sclerosis by the European Commission
28 augusti 2020
Viken – 28th August 2020 – TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted…
First patient treated with ILB in TIKOMED’s clinical trial for ALS
2 november 2018
Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological…
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
20 augusti 2018
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological…